MSD has received US Food and Drug Administration (FDA) approval for its anti-programmed death receptor-1 (PD-1) therapy, ...

Phase 2 study, led by Dr. Antonio Jimeno at the University of Colorado Anschutz Medical Campus will evaluate NT219 in ...

The PD-L1 Inhibitors drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being ...

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the ...

Merck ( MRK) is a global biopharmaceutical giant with a diversified portfolio that spans across oncology, vaccines, ...

A breast cancer patient self funding her treatment has said it's unfair she has to pay GST on the drugs that are already costing her ten of thousands of dollars. Wellington woman Amanda Broughton has ...

China, already gaining speed in biotechnology, is looking to further accelerate novel drug development by reducing the time ...

Lantern Pharma (NASDAQ: LTRN) announced a remarkable clinical outcome in its Phase 2 HARMONIC(TM) trial, with a 70-year-old never-smoker with advanc ...

Is it fair to pay $8500 every three weeks to stay alive, including 15 percent GST, woman asks.

The recent experience of Chinese biotech companies in developing their own drug candidates and inking deals with larger ...

DelveInsight’s Anaplastic Thyroid Cancer Pipeline report depicts a robust space with 8+ active players working to develop 8+ ...

Douglas Adkins, MD, discusses future directions of the KEYNOTE-689 trial of pembrolizumab in head and neck cancer following the agent's FDA approval.